drugset
drugset / Trial / NCT04497168

Citalopram as a Posterior Cortical Protective Therapy in Parkinson Disease

NCT04497168 ↗

Phase 2 Completed 58 enrolled University of Michigan National Institute on Aging (NIA) · collab
RandomizedParallel-groupDouble-blindPrevention

Summary

This Parkinson disease (PD) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive impairment in PD.

Timeline

Start
2021-04-01
Primary completion
2026-03-02
Completion
2026-03-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Citalopram Small molecule 20 mg —

Indications

Parkinson disease